A Combination of Rapamycin and Trametinib Extended Maximum Lifespan by up to 35%

News
#179

@ Ray1
Actually most precancerous lessions never become an aggressive cancer.

Even cancer usually don’t kill - for example: prostate cancer and thyroid cancer are quite often present in people 80 years+, but they kill very rarely (prostate cancer is seen in most of people above 70, but only about 2% will die from it)

It is called overdiagnosis (when diagnosis is correct but still nothing will happen from that - doctors prefer to overdiagnose than underdiagnose, because it is hard to tell which precancerous lession will become cancerous and which won’t)

For example: Thyroid cancer diagnoses in South Korea increased 15-fold between 1993 and 2011 - but amount of people who died from thyroid cancer is the same - but now 15x more people know that they have the disease

3 Likes
#180

Since intestinal metaplasia usually fails to progress to full blown stomach cancer, most people who have it will die of something else first. This is why a Trametinib trial for intestinal metaplasia is seen as irresponsible and will not happen any time soon. Why give a drug with dangerous side effects to a person who probably will not develop cancer? The counter argument is that detecting and stopping cancers before they develop would be much more effective than spending a fortune treating advanced metastatic cancers in vain… Right now the economics of early detection are questionable, but with better early detection and early interventions that work, the economics could flip.

2 Likes